Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Wählen Sie die gewünschte Spezies
Human HER2 Protein expressed in Human Cells - ABIN2001860
Yamamoto, Ikawa, Akiyama, Semba, Nomura, Miyajima, Saito, Toyoshima: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. in Nature 1986
Show all 9 Pubmed References
Human HER2 Protein expressed in Wheat germ - ABIN1353011
He, Qu, Shen, Tan, Zeng, Liu, Jiang, Li: Highly specific recognition of breast tumors by an RNA-cleaving fluorogenic DNAzyme probe. in Analytical chemistry 2015
Show all 2 Pubmed References
Human HER2 Protein expressed in HEK-293 Cells - ABIN2181214
NDong, Tate, Kett, Batra, Demidenko, Lewis, Hoopes, Gerngross, Griswold: Tumor Cell Targeting by Iron Oxide Nanoparticles Is Dominated by Different Factors In Vitro versus In Vivo. in PLoS ONE 2015
Show all 4 Pubmed References
Human HER2 Protein expressed in HEK-293 Cells - ABIN2181216
Piechocki, Wu, Jones, Jacob, Gibson, Ethier, Abrams, Yagita, Venuprasad, Wei: Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA. in International journal of cancer. Journal international du cancer 2012
Show all 4 Pubmed References
Human HER2 Protein expressed in Human Cells - ABIN2001858
Lai, Lemke: An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system. in Neuron 1991
Show all 6 Pubmed References
1year of adjuvant trastuzumab treatment conferred substantial survival benefits and should remain as the preferred treatment for early stage HER2-positive breast cancer.
Resistance was overcome by combining ER-directed therapy with the irreversible HER2 kinase inhibitor neratinib.
HER2 amplification was predictive of anti-EGFR therapy response and appeared to be prognostic in metastatic colorectal cancer patients.
Inhibition of ezrin synergizes with lapatinib in a PKCalpha-dependent fashion to inhibit proliferation and promote apoptosis in HER2-positive breast cancer cells.
Gene alterations, such as TP53 mutation, PIK3CA mutation, ERBB2 amplification and CCND1 amplification, and MAPK pathway alteration were associated with pCR in our study.
We demonstrated a positive prognostic impact of HER2 overexpression in a large cohort of esophageal adenocarcinoma (EAC), contrary to other solid malignancies including gastric cancer and breast cancer, but consistent to the results of a large study on EAC from 2012.
identify the presence of intratumoral heterogeneity of ERBB2 amplification and HER2 expression in Micropapillary urothelial carcinoma
NVP-AUY922 displays potent anti-cancer activity in HER2-positive and trastuzumab-resistant breast cancer cells.
HER2 is generally upregulated in human meningiomas, but in an activated state only.
Our data also suggests that PID quantitation of HER2 protein may offer an improvement over conventional HER2 testing in the selection of patients who will be the most likely to benefit from HER2-targeted therapy. Further studies with a larger cohort are warranted.
Dual EGFR/HER2 knockdown by siRNAs further decreased the growth of Gastric Cancer cells treated with gefitinib alone, confirming that single-agent drug targeting does not achieve a maximal biological effect.
Relative to ER, PR and HER2 from medical records, central IHC staining and the addition of Ki67 or combined tumor grade improved accuracy for classifying PAM50-based luminal subtypes.
HER2 amplification is a distinct driver event seen in all breast cancer subtypes, rather than a subtype marker, with major characteristics restricted to amplification and overexpression of HER2 and neighboring genes. The HER2E subtype has a distinctive transcriptional landscape independent of HER2A that reflects androgen receptor signaling as replacement for estrogen receptor (ER)-driven tumorigenesis.
Study recommend that measuring RANKL together with HER2 in blood samples can be routinely applied to allow early detection of bone metastases in patients with breast cancer.
Study demonstrates that HER2 mRNAs post-transcriptionally up-regulate HER3 via the sequestration of miR-125a/b, contributing to enhanced breast cancer growth and acquired anti-HER2 resistance.
Performed in mice bearing subcutaneous HER2-overexpressing and low HER2-expressing tumors.
Increased platelet-to-lymphocyte ratio was a poor prognostic factor for both overall survival (OS) (primary endpoint) and failure-free survival (FFS) and warrants further investigation into its prognostic ability amongst patients with HER2-positive metastatic breast cancer
Interaction between RhoGDI1 and ephrinB1 promotes cancer cell migration and invasion through RhoA activation.
High HER2 expression promotes gastric cancer invasion and metastasis.
Aggressive adjuvant systemic treatments should be considered for patients with HER2-rich and triple-negative subtype who exhibit tumor shrinkage in NAC but still have high levels of Ki67.
Caloric restriction significantly impacts Estrogen receptor and ErbB2 signaling, which induces profound changes in mammary epithelial cell reprogramming, and mammary stem/progenitor cell inhibition is a critical mechanism of caloric restriction-mediated breast cancer prevention
High HER2 expression is associated with metastasis in breast Cancer.
Study shows that within endoplasmic reticulum-related subsurface cistern, sigma-1 receptors, Kv2.1 and neuregulin-1 are clustered in highly specific, non-overlapping, microdomains, whereas ErbB2 and ErbB4 are present in the adjacent presynaptic compartment. This organization may define highly ordered and spatially restricted sites for different signal-transduction pathways.
ErbB2 interacts with Nrp1 to form a Sema3d co-receptor expressed by developing coronary endothelium and required for proper connections of the forming coronary veins to the right atrium.
The objective of this study was to determine if loss of Stard13 plays a role in mammary tumor progression using transgenic mice expressing the activated ErbB-2 (Neu) oncogene and Cre recombinase (NIC) in mammary epithelium under transcriptional control of the murine mammary tumor virus (MMTV) promoter (MMTV-NIC).
Over-expression of HER2 remarkably enhanced the proliferation, invasion and migration of B16 cells.
YAP accumulated in nuclei of mammary glands in ErbB2/EGFR-transgenic mice, suggesting that EGFR signaling affects YAP in vivo similar to cell culture. ErbB2/EGFR-transgenic mice develop mammary tumors in 7-8 months, but surprisingly, MaSCs from these mice did not form tumors when transplanted into host mice.
Results indicate the importance of the LDL receptor (LDLR) in the growth of triple-negative and HER2-overexpressing breast cancers in the setting of elevated circulating LDL cholesterol (LDL-C).
caErbB2 markedly enhances regeneration of damaged dorsal roots, while evoking little change in intact roots
immunocompetent mouse models of HER2/ErbB2-driven breast cancer, CD73 expression by tumor cells and host cells significantly suppressed immune-mediated responses mediated by anti-ErbB2 mAb.
We further demonstrate that loss of one allele of PTEN is sufficient to shift isoform dependency from p110alpha to p110beta in vivo. These results provide insight into the molecular mechanism by which ErbB2-positive breast cancer escapes p110alpha inhibition.
sought to further echocardiographically characterize the ErbB2(tg) mouse line as a model of hypertrophic obstructive cardiomyopathy
investigations revealed that NUMB and NUMBL interacted with small GTPase Rab7 to transition ERBB2 from early to late endosome for degradation.
Combined targeting of TGF-beta, EGFR and HER2 signaling suppresses lymphangiogenesis and metastasis in a pancreatic ductal adenocarcinoma model.
The conjugation of benzylguanine-modified auristatin F to EGFR-specific 425(scFv)-SNAP and HER2-specific alphaHER2(scFv)-SNAP resulted in two potent recombinant antibody-drug conjugates that specifically killed breast cancer cell lines by inducing apoptosis when applied at nanomolar concentrations.
ErbB2 is required for neonatal cardiomyocyte proliferation. ErbB2 conditional knockout heart exhibited an upregulation of negative cell cycle regulators.
Despite previous evidence suggesting that ErbB receptors can bind and activate IRSs, our findings indicate that ErbB2 does not cooperate with the IRS pathway in mouse breast cancer model.
It was suggested that transgenic HER-2/neu involves in initiation of malignization of mammary epithelial cells but also in acceleration of age-related hormonal and metabolic changes in turn promoting mammary carcinogenesis
Study showed that suppression of STAT3, STAT5, and STAT6 and overexpression of the proapoptotic factor STAT1, which provides p53-mediated apoptosis, are the causes for increasing the number of apoptotic neurons in physiological aging. HER-2 tyrosine kinase receptor overexpression promotes neuronal survival through activation of STAT-signaling pathway with simultaneous suppression of the proapoptotic factor STAT1
Loss of zinc finger protein multitype 1 (Zfpm1) activity resulted in over-activation of Neuregulin-ErbB signaling and abnormally elevated cardiomyocyte proliferation.
Newly synthesized N-cadherin molecules move from the lateral to the basal surface of cardiomyocytes during trabeculation. This localization requires Erbb2 signaling.
these results suggest that Nrg1 is not the primary effector of trabeculation and/or that other EGF-like ligand(s) activates the ErbB2/ErbB4 pathway, either through functioning as the primary ligand or acting in a redundant manner. Overall, our work provides an example of cross-species differences in EGF family member requirements for an evolutionary conserved process.
Embryos homozygous for a GBT insertion within neuregulin 2a (nrg2a) revealed a novel requirement for a Neuregulin 2a (Nrg2a)-ErbB2/3-AKT signaling pathway governing the organization of a subset of epidermal cells during median fin fold morphogenesis.
A direct link was found between Erbb2 activity and remodeling of myofibrils.
Study shows that, in addition to its role in cardiomyocyte proliferation, ErbB2 is also required for regulating cardiomyocyte migration (delamination) to initiate cardiac trabeculation.
erbb3 and erbb2 are essential for schwann cell migration and myelination in zebrafish.
NRG1 and PI3K functionally interact with ErbB2 and ErbB3 during regeneration
Results indicated that most periocular squamous cell carcinomas of horses expressed epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2).[HER2]
Widespread expression of ErbB2 receptor mRNAs was found throughout the telencephalon of juvenile and adult monkeys with in situ hybridization, with higher levels in grey matter compared to white matter.
We have isolated the cDNA encoding the rhesus monkey homolog of human Her2/neu (RhErbB2) to construct DNA plasmids and adenoviral vectors for the development of a cancer vaccine against this protein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
c-erb B2/neu protein
, metastatic lymph node gene 19 protein
, neuro/glioblastoma derived oncogene homolog
, neuroblastoma/glioblastoma derived oncogene homolog
, proto-oncogene Neu
, proto-oncogene c-ErbB-2
, receptor tyrosine-protein kinase erbB-2
, tyrosine kinase-type cell surface receptor HER2
, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
, Neu oncogene
, avian erythroblastosis oncogene B 2
, proto-oncogene NEU
, Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog)
, NEU proto-oncogene
, epidermal growth factor receptor-related protein
, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
, epidermal growth factor receptor type 2